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ABSTRACT
Acute heart failure (AHF) is a life-threatening medical condition, where urgent diagnostic 
and treatment methods are of key importance. However, there are few evidence-based 
treatment methods. Interestingly, despite relatively similar ways of management of AHF 
throughout the globe, mid-term outcome in East Asia, including South Korea is more 
favorable than in Europe. Yet, most of the treatment methods are symptomatic. The 
cornerstone of AHF management is identifying precipitating factors and specific phenotype. 
Multidisciplinary approach is important in AHF, which can be caused or aggravated by 
both cardiac and non-cardiac causes. The main pathophysiological mechanism in AHF is 
congestion, both systemic and inside the organs (lung, kidney, or liver). Cardiac output is 
often preserved in AHF except in a few cases of advanced heart failure. This paper provides 
guidance on AHF management in a time-based approach. Treatment strategies, criteria for 
triage, admission to hospital and discharge are described.
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INTRODUCTION
Recent guidelines from European Society of Cardiology (ESC) and American College of 
Cardiology Foundation/American Heart Association (ACCF/AHA) and guidance papers from 
European Society of Emergency Medicine (EUSEM), European Society of Intensive Care 
Medicine (ESICM) have provided updated recommendations on acute heart failure (AHF) 
management.1-4) However, there is still a lack of evidence in the field and physicians frequently 
have to make decisions based on expert opinion consensus, rather than evidence-based 
recommendations. Management of AHF relies on rapid recognition of the symptoms, identifying 
the underlying or precipitant cause, assessing severity of AHF, recognizing complications and 
initiating specific treatment as soon as possible. Both ESC and ACCF/AHA guidelines underscore 
that, similarly to acute coronary syndrome (ACS), AHF patients might benefit from “time-to-
therapy” concept.1)2) Consequently, rapid diagnosis and immediate treatment can be potentially 
lifesaving in these patients, thus exact time-based algorithms must be in place in pre-hospital 
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and hospital settings. Recently, an interest in acute right heart failure (HF) has developed, since it 
has distinct clinical features, its own diagnostic difficulties and treatment.5)
Although it is necessary to follow similar strategies of managing AHF throughout the world, 
one should keep in mind that there are regional differences. We recently showed that patients 
from East Asia had a better 1-year survival following an AHF admission than European 
patients in an analysis including more than 18,000 patients.6)
This paper summarizes recommendations from most recent ESC, ACCF/AHA guidelines and 
EUSEM, ESICM guidance papers and provides contemporary perspective based on state-of-
art clinical trials.
DEFINITION
AHF is a rapid onset or acute worsening of symptoms and/or signs of HF, associated 
with elevated plasma levels of natriuretic peptides (NPs).1) It requires immediate medical 
management and, usually, urgent hospital admission. It can be a first occurrence of AHF 
(de novo) or, more frequently, acute decompensation of chronic heart failure (ADHF). De 
novo AHF is mainly caused by primary cardiac dysfunction (mainly ACS), while ADHF may 
be precipitated by infection, uncontrolled hypertension, rhythm disturbances or non-
compliance with the prescribed drugs/diet.1)2) AHF is a multifaceted syndrome with various 
clinical phenotypes, such as acute pulmonary edema (APE), hypertensive HF, cardiogenic 
shock (CS) and others.7) It may present with impaired or preserved left ventricular ejection 
fraction, or disturbance of right ventricle function. Although considered as a primarily 
cardiac syndrome, AHF may lead to systemic disorders and affect all vital organs due to 
insufficient blood circulation4) caused by high level of venous back-pressure and/or low 
cardiac output.
CLASSIFICATION
Nomenclature of AHF depends on the criteria used. Guidelines suggest that the most useful 
classifications in practice are those that rely on clinical presentation.1)2) They help clinicians 
to identify the patients at high risk and initiate the necessary treatment rapidly. Most AHF 
patients present with normal or high blood pressure (BP) and symptoms/signs of congestion. 
Only 5–8% patients present with hypotension, which is associated with poor prognosis, 
especially if accompanied with hypoperfusion.1) Hypotension (systolic blood pressure [SBP] 
<90 mmHg or >90 mmHg maintained by vasopressors) with the absence of hypovolemia and 
signs of hypoperfusion (cold sweated extremities, oliguria, altered mental state, metabolic 
acidosis, etc.) is defined as CS. Although relatively rare, CS is the most severe form of AHF, 
treated in the coronary care unit (CCU)/intensive care unit (ICU). With delayed treatment, CS 
may initiate systemic inflammatory responses, leading to multiorgan failure and death.
Another possible approach is classifying patients based on precipitating factors or causes 
leading to decompensation, which have their specific treatments and need to be corrected 
urgently (Table 1).1)2) Moreover, 2 main mechanisms causing organ dysfunction in AHF are 
congestion, which is very frequent, and hypoperfusion, which is rather rare. Classification 
based on bedside clinical examination evaluates the symptoms or signs of congestion (“dry” 
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vs. “wet”) and/or peripheral hypoperfusion (“warm” vs. “cold”).8) This approach divides the 
patients into 4 groups, which helps guide the treatment in the initial phase and also has 
prognostic value (Table 2).8-10) Classifications based on clinical presentation are intended to 
provide personalized care for the AHF patient.
MANAGEMENT OF ACUTE HEART FAILURE  
(EXCLUDING CARDIOGENIC SHOCK)
First hour management
Patients with AHF are at high risk of complications during the first hour of the onset of the 
disease.11) Therefore, it is increasingly acknowledged that “time-to-treatment” approach, 
which is highly established in ACS, should be considered in AHF to prevent adverse 
outcomes.12)13) Indeed, early prehospital treatment is associated with lower mortality.14) 
Urgent treatment is also important to prevent de novo AHF patients from developing chronic 
HF.4) Patients should be rapidly transferred to the hospital, preferably to a center with a 
cardiology department and/or emergency department (ED) or CCU/ICU with AHF expertise.4) 
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Non-compliance with the treatment plan, sodium and/or fluid restriction
Excessive use of toxic substances
Drugs exacerbating condition (e.g., calcium channel blockers, steroids, NSAIDs)
Exacerbation of COPD
PE
Metabolic or hormonal disorders
Cerebrovascular accident
Acute mechanical cause
Additional acute cardiovascular causes (e.g., pericardial effusion, myocarditis)
ACS = acute coronary syndrome; AHF = acute heart failure; COPD = chronic obstructive pulmonary disease;  
PE = pulmonary embolism.
Table 2. Clinical classification and appropriate treatment based on bedside clinical examination
Evidence of congestion
Pulmonary congestion, orthopnea/paroxysmal nocturnal dyspnea, peripheral edema,  
distended jugular veins, rales, hepatojugular reflux, ascites
Congestion (−) Congestion (+)
Evidence of hypoperfusion: 
narrow pulse pressure, 
symptomatic hypotension, 
cool extremities,  
impaired mental status
Hypoperfusion (−) Warm-dry (up to 25%) Warm-wet (up to 50%)
Compensated Predominant congestion Predominant hypertension
1. Adjust oral therapy 1. Diuretic 1. Vasodilator
2. Vasodilator 2. Diuretic
3.  Consider ultrafiltration if resistant 
to diuretics
Hypoperfusion (+) Cold-dry (up to 5%) Cold-wet (up to 20%)
Hypoperfused and hypovolemic SBP <90 mmHg SBP ≥90 mmHg
1. Consider fluid challenge 1. Inotropic agent 1. Vasodilator
2.  Consider inotropic agent if 
hypoperfusion persists
2. Vasopressor in refractory cases 2. Diuretic
3.  Diuretic (when perfusion restored) 3.  Consider inotropic agent in 
refractory cases
4.  Consider mechanical circulatory 
support if unresponsive to drugs
Adapted from the 2016 ESC guidelines on acute and chronic HF.1) This approach was proposed by the analysis of Nohria et al.10) Frequencies of the groups are 
given according to this analysis.
ESC = European Society of Cardiology; HF = heart failure; SBP = systolic blood pressure.
Immediate and concomitant investigation, diagnostic tests, pharmacologic and non-
pharmacologic treatment should be initiated on the arrival (Figure 1).
Initial clinical evaluation
In the earliest stages of diagnostic workup, emphasis should be given to determination 
of cardiopulmonary stability based on dyspnea severity, hemodynamic status and heart 
rhythm.1)4) This may be achieved by following assessments:
• Respiratory rate, orthopnea, accessory muscles use in respiration, visible cyanosis, pulse 
oximetry as objective measurements of respiratory distress
• Audible rales as sign of pulmonary congestion
• SBP and diastolic blood pressure (DBP)
• Heart rate and rhythm
• Objective determination of body temperature and signs/symptoms of hypoperfusion3)
Patients with respiratory failure or hemodynamic compromise should be transferred to a 
location where immediate respiratory and cardiovascular support is available. When AHF 
is caused by acute myocardial infarction, patient must be referred to the closest clinical 
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Figure 1. Time-based management in AHF. 
ACS = acute coronary syndrome; AHF = acute heart failure; ECG = electrocardiogram; HFOT = heart failure oral 
therapy; NIV = non-invasive ventilation.
facility, where round-the-clock cardiac catheterization service is available.4)15) If CS is 
present, patient should receive ventilation and hemodynamic support and be transferred 
directly to CCU/ICU.16)
Next, patient should be examined for signs of systemic congestion, such as peripheral 
edema, jugular venous dilatation and others (Table 2).
Additional tests used in patients with suspected AHF include:
1) Electrocardiogram (ECG)
Electrocardiogram (ECG) will exclude ST-segment elevation myocardial infarction (STEMI) 
and other high risk changes.1) Additional ECG value is limited, since it is rarely normal in 
those with suspected AHF and may reveal some chronic abnormality.3)
2) Imaging modalities
• Bedside thoracic ultrasound: With expertise, thoracic ultrasound can be a useful diagnostic 
tool for visualizing directs signs of interstitial edema.17) Pulmonary congestion may be 
assessed by analyzing comet-like vertical reverberation artefacts, called B-lines.18) The 
quantity and diffusion of B-lines provides a semi-quantitative estimation of extravascular 
lung water (≤5, absent; 6–15, mild degree; 16–30, moderate degree; >30, severe pulmonary 
edema).18) B-lines are useful in differential diagnosis between AHF and non-cardiac causes 
of dyspnea.19)
• Chest X-ray: It is one of the most used modalities in AHF settings. Most specific signs of 
AHF are pulmonary venous congestion, pleural effusion, interstitial or alveolar edema 
and cardiomegaly.1) However, sensitivity of chest radiography is limited, since it may be 
completely normal in almost 20% of the cases.20)21) If expertise is available, lung ultrasound 
may be more sensitive and timesaving modality in detecting interstitial edema.3) Chest 
radiography can also identify alternative etiology of dyspnea, such as pneumonia or other 
pulmonary infections.
• Echocardiography: Immediate cardiac ultrasound is mandatory in all patients with CS and 
when acute life-threatening structural or functional cardiac abnormalities (mechanical 
complications, aortic dissection, etc.) are suspected.1)3) In other cases, it may be performed 
later during hospitalization, when expertise is available (preferably, during first 48 hours of 
admission). Early echocardiography should be pursued in de novo AHF patients and those, 
whose cardiac function is unknown.1)
• Chest computed tomography (CT): Though not particularly relevant in diagnosing AHF, 
thoracic CT scan is essential, when pulmonary embolism (PE) is suspected as a precipitating 
factor of AHF.22)
3) Laboratory tests
• NPs: Plasma NP level (B-type natriuretic peptide, N-terminal pro-B-type natriuretic 
peptide, or mid-regional pro-atrial natriuretic peptide) should be measured at 
presentation to the ED or CCU/ICU in all patients with acute dyspnea and suspected AHF. 
Due to their high sensitivity, NPs are very important in ruling out AHF as an etiology 
of acute dyspnea, since detecting normal levels makes AHF diagnosis improbable.3)23) 
However, there are numerous cardiac and non-cardiac causes, which may be associated 
with elevated plasma NP level. Therefore, a higher value of NP does not automatically 
confirm the diagnosis of AHF and interpretation of their levels must be combined with 
clinical assessment and cardiac imaging.4) NPs have prognostic value in AHF: higher 
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concentrations mean more severe condition and increased risk for readmission and 
mortality.24)
• Cardiac troponins: They are useful for detection of ACS as the precipitator of AHF.1) 
Elevated troponin levels are also associated with poorer outcomes in AHF.25)26)
• The following laboratory assessments should be performed at admission in all patients 
with AHF: blood urea nitrogen (BUN)/urea, creatinine, electrolytes (sodium, potassium), 
liver function tests, glucose, and complete blood count.3) Abnormal liver function tests 
reflect different clinical profiles in AHF. Elevated cholestasis markers are associated with 
signs of systemic congestion, right HF and higher concentration of creatinine and NPs, 
whereas increased levels of alanine aminotransferase, aspartate aminotransferase — with 
signs of hypoperfusion and consequent liver cell damage.27) Deteriorated kidney function 
is a frequent comorbidity of AHF, which worsens the prognosis.28) ESC guidelines also 
recommend performing thyroid-stimulating hormone (TSH), since both hypothyroidism 
and hyperthyroidism may precipitate AHF.1)
• Although not needed in most cases, arterial blood gas may be useful in severe cases of 
hemodynamic instability and respiratory distress. Acid-base balance should be obtained 
on admission, especially in patients with APE or previous history of chronic obstructive 
pulmonary disease (COPD).3) If respiratory distress persists despite initial therapy with 
oxygen and/or non-invasive ventilation (NIV), venous blood gas analysis is sufficient to 
detect respiratory or metabolic acidosis.29)
• There are multiple novel biomarkers (sST2, Galectin-3, GDF-15, etc.) being investigated in 
AHF, but they have yet to be introduced to routine clinical practice.
Initial therapy
1) Oxygen therapy and/or ventilatory support
Oxygen saturation (SpO2) should be monitored in all patients with dyspnea. Oxygen therapy 
should be initiated when SpO2 is below 90% and fraction of inspired oxygen (FiO2) should be 
increased up to 100%, if necessary, according to SpO2 measurements. However, hyperoxia 
causes vasoconstriction and may decrease coronary and cerebral blood flow and thus should 
be avoided.30)
NIV is indicated in patients with respiratory distress and should be initiated urgently, 
since it reduces respiratory distress and rate of mechanical endotracheal intubation.31) In 
a randomized study comparing early versus delayed NIV, initiation of continuous positive 
airway pressure (CPAP) in pre-hospital settings in patients with cardiogenic APE significantly 
improved clinical dyspnea score, partial pressure of oxygen (PaO2) levels and reduced tracheal 
intubation rates and in-hospital mortality.32) However, potential benefit of NIV on reducing 
mortality has only been shown in small-sample trials and larger trials are needed.33) Two 
main methods of NIV include CPAP and bi-level positive pressure ventilation (PPV).34) CPAP 
has a simpler technology and less expensive equipment than bi-level PPV. In turn, bi-level 
PPV devices consist of a higher inspiratory positive airway pressure and a lower expiratory 
pressure, providing inspiratory aid.34) The 2017 European Respiratory Society/American 
Thoracic Society guidelines recommend either of the NIV methods in acute respiratory 
failure due to cardiogenic APE and suggest initiating NIV in pre-hospital settings.34) In 
acidotic patients due to COPD exacerbation, bi-level PPV is recommended.34) NIV is 
contraindicated in patients with respiratory arrest, decreased conscious state or significant 
hemodynamic instability.35) Other contraindications include lack of staff expertise or patient's 
cooperation, vomiting and possible pneumothorax.4) Patients with these conditions and 
those unresponsive to NIV should be intubated.
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2) Diuretics
Intravenous loop diuretics are a key of symptomatic treatment in AHF patients with signs 
of significant fluid overload and congestion.1)2) They increase renal salt and water excretion, 
have vasodilator properties and provide rapid decongestion and symptomatic relief.1) 
Intravenous furosemide is the first-line diuretic in most of the cases. ACCF/AHA guidelines 
recommend administering diuretics immediately upon presentation, as this approach may 
be associated with better outcomes.2) However, there is little evidence defining optimal 
diuretic timing, dosage and method of delivery.1) In the Diuretic Optimization Strategies 
Evaluation (DOSE) trial, there were no statistically significant differences in symptom relief 
and creatinine levels in bolus vs. continuous diuretic infusion and in high-dose vs. low-dose 
groups.36) In the “high-dose” arm of the trial, patients were administered furosemide at 2.5 
times their previous oral dose. This resulted in greater improvement in diuresis and dyspnea 
at the cost of transient worsening in renal function.36) It is therefore recommended to limit 
diuretic dose to the smallest amount needed to provide adequate symptomatic relief and 
modify the dose according to renal function and prior dose of diuretics.1-4) Hence, de novo 
AHF or diuretic naïve patients should receive initial intravenous furosemide bolus of 20–40 
mg, while patients on chronic oral diuretic therapy should be administered intravenous 
bolus of at least equal to their oral dose.1)3) If the patient is not hypotensive, combination with 
vasodilator agent for dyspnea relief may be used. In cases of diuretic resistance, dual nephron 
blockade by loop diuretics and thiazide diuretics or natriuretic doses of mineralocorticoid 
receptor antagonists (MRAs) may be administered for better effect.37)38) However, these 
combinations may cause hypokalemia, renal dysfunction or hypovolemia, therefore cautious 
electrolyte, renal function, and fluid balance monitoring is required. If diuretic agents do 
not provide the expected effect, ultrafiltration may be considered,37)38) but prognosis of this 
approach is poor.39) In patients with AHF and signs of hypoperfusion, clinicians should 
refrain from diuretics before adequate perfusion is restored.1)
3) Vasodilators
Intravenous vasodilators, predominantly nitrates, provide additional symptomatic relief 
to diuretics and are the second most used drugs in AHF.3) Nitrates have a dual mechanism 
of action as they act as both venodilators and arteriodilators, reducing both preload and 
afterload and as a result increasing stroke volume.1)4) Intravenous vasodilators are especially 
indicated in hypertensive AHF.1) Previous ESC guidelines restricted vasodilators use in 
patients with SBP <110 mmHg;40) this has been changed — 2016 ESC guidelines recommends 
avoiding vasodilators when SBP is <90 mmHg or hypotension in symptomatic.1) ESICM 
guidance recommends initiating vasodilators as soon as possible in patients with normal 
to high BP;4) a delay of vasoactive drugs administration has been associated with higher 
mortality.13) Furthermore, initiation of intravenous vasodilators urgently after presentation 
has been shown to reduce the rates of mechanical ventilation and risk of adverse events 
(AEs).13)41)
Recent randomized controlled trials have challenged the use of agents with vasodilator 
properties in AHF. In Trial of Ularitide Efficacy and Safety in Acute Heart Failure (TRUE-AHF) 
study, patients were randomly assigned to receive continuous intravenous infusion of either 
ularitide or matching placebo for 48 hours, in addition to adequate AHF therapy.42) There 
were no differences in co-primary outcomes (cardiovascular mortality over the 15 months 
of the trial and the clinical course during the initial 48 hours evaluated by hierarchical 
clinical composite outcome) between the 2 trial arms. Ularitide did not show benefit in any 
of the clinical secondary outcome measures either. In a post hoc analysis, which excluded 
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the patients, which had been randomized despite being ineligible for the trial, ularitide 
was shown to improve hierarchical clinical composite outcome but still did not reduce the 
risk of cardiovascular mortality.42) Although RELAXin in Acute Heart Failure (RELAX-AHF) 
trial findings were promising for another vasodilator agent serelaxin,43) a subsequent larger 
RELAX-AHF-2 trial (NCT01870778) did not meet either of its primary endpoints, which were 
180-day cardiovascular mortality and worsening HF in the first 5 days.44)45) A novel calcium 
channel blocker with vasodilator properties clevidipine safely and rapidly reduced BP and 
improved dyspnea more effectively than standard-of-care intravenous antihypertensive 
therapy in patients with hypertensive AHF in a pilot Prioritising Responses of Nurses to 
Deteriorating Patient Observations (PRONTO) study.46) Nonetheless, due to relatively 
small sample size, open-label design, and short follow-up time, these findings have to be 
confirmed in larger randomized controlled trials.47)
Vasodilators are contraindicated in shock and should be used cautiously when significant 
mitral or aortic valvular stenosis is suspected or in predominant right ventricular (RV) 
failure.4)
4) Other agents
Even though they relieve dyspnea and anxiety, routine use of opiates is not recommended in 
AHF.1) In the Acute Decompensated Heart Failure National Registry (ADHERE), morphine 
use was associated with higher rates of mechanical ventilation, ICU admission and death.48)
As noted in the ESC guidelines, administration of vasopressor in AHF (excluding CS) should 
be restricted to patients with hypotension and administration of sympathomimetic — to 
patients with signs of low cardiac output.1) In the recent international European Society of 
Cardiology Heart Failure Long-Term Registry (ESC-HF-LT) registry49) the use of inotropes 
and/or vasopressors was lower than in previous registries (12% vs. 20% in Italian Italian 
Network on Heart Failure [IN-HF] Outcome registry50) and 33% in global Acute Heart Failure 
Global Registry of Standard Treatment [ALARM-HF] registry51)). Nonetheless, the use of 
these drugs was still inappropriate as only a small number of the treated patients had CS and 
less than half had signs of peripheral hypoperfusion.49) In analysis with propensity-based 
matched pairs from this registry, patients receiving intravenous inotrope and/or vasopressor 
had a higher long-term mortality risk compared to those who did not. The findings also 
showed that dopamine had the greatest negative association with mortality among studied 
inotropes (dobutamine, levosimendan), but the study was not powered to prove such 
results.49)
First day management
After initial diagnostic tests and symptomatic treatment of the urgent symptoms, clinicians 
should seek to rapidly identify the etiology or precipitating factor for AHF and initiate the 
specific treatment (Figure 1). This is extremely important to prevent worsening of AHF and avoid 
adverse outcomes and should be achieved within the initial few hours of AHF management.1)2)
Precipitating factors and their specific treatment
• ACS: It is a frequent cause of both acutely decompensated HF and de novo AHF.52) 
ECG may rapidly reveal STEMI, however, diagnosis of other ACS cases may be more 
complicated.2) Troponin levels are elevated in many patients with AHF with or without 
ACS as the sensitivity of troponin assays increases.53) ACCF/AHA guidelines recommend 
considering coronary angiography in all patients with newly diagnosed HF.2) We 
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recommend to consider this when patient is stabilized. Patients with coexistent ACS (both 
non-ST elevation ACS and STEMI) and AHF are at a very-high risk group and immediate 
revascularization is indicated, regardless of other findings.1)15)54)
• Severe arrhythmias/rhythm disturbances. Tachyarrhythmia, bradyarrythmia or conduction 
disturbances may precipitate AHF. Several ESC guidelines address the management 
of severe rhythm disturbances.55-57) Urgent electrical cardioversion is recommended 
if arrhythmia is related to hemodynamic instability. In AHF patients with atrial 
fibrillation (AF) and rapid ventricular rate (>110 bpm), intravenous boluses (0.25–0.5 mg 
intravenously, smaller doses of 0.0625–0.125 mg in patients with moderate to severe renal 
dysfunction) of digoxin should be considered for rapid control of the ventricular rate.1) In 
other patients with HF and AF, beta blockers are preferred to control the ventricular rate.3)
• Acute mechanical causes: They include complications of ACS (e.g., free wall or 
ventricular septal rupture, acute mitral insufficiency), chest trauma, cardiac intervention, 
endocarditis (acute native or prosthetic valve lesion), aortic dissection and rarer causes of 
obstruction (e.g., cardiac tumors). Immediate echocardiography is crucial to confirm the 
diagnosis when acute mechanical cause is suspected and treatment comprises of urgent 
surgical or percutaneous repair.1)15)
• Acute PE: Pulmonary embolus should be considered as a precipitant of AHF since patients 
with HF are more likely to be in a hypercoagulable state.2) Chest CT is a gold standard in 
the diagnostic process.22) When acute PE is confirmed, immediate primary reperfusion is 
recommended. This may be achieved by thrombolysis, catheter-based approach or surgical 
embolectomy.22)
• Infection: Respiratory infections are frequent precipitants for HF.58) They cause hypoxia 
and are associated with higher in-hospital and long-term mortality.58)59) Sepsis is 
associated with reversible left ventricle hypokinesia.60) Procalcitonin is useful in diagnosis 
of primary or coexisting respiratory infection in dyspneic patients and guiding the 
initiation of antibiotic treatment.61)62) Significantly elevated procalcitonin levels predict 
worse in-hospital outcomes and increased 30-day mortality, irrespective of HF severity.63) 
Rapid detection of bacterial infections and initiation of specific antibiotic treatment is 
essential to prevent adverse outcomes in patients with AHF.
Determining necessary level of care for acute heart failure patient
AHF patients need different levels of care (discharge, observation, ward, ICU, etc.) depending 
on the severity of their condition. Algorithms and risk scores aimed at predicting in-hospital 
mortality may provide additional value to clinical judgment in the decision process. The 
ADHERE registry including more than 65,000 patients developed an algorithm predicting 
in-hospital mortality in patients with HF.64) It consists of measurements of BUN, SBP, and 
creatinine and helps identify high risk population that should be referred to ICU. Moreover, 
low risk population may be identified by the absence of high risk features (high plasma NP 
levels, hypotension, positive troponin, deteriorated renal function, etc.). These patients can 
be treated in the observation unit to evaluate the response to the initial therapy.3) EUSEM 
guidance provides a list of indicators of good response to therapy to consider in ED:
• Subjective improvement noted by patient
• Resting heart rate <100 bpm
• No orthostatic hypotension
• Adequate urinary output
• SpO2 >95% in room air
• No or moderate worsening of renal function (chronic renal disease might be present)3)
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The following criteria are recommended for admitting the patient to ICU/CCU:
• Need for intubation (or already intubated)
• Evidence of organ hypoperfusion
• SpO2 <90% on oxygen therapy
• Increased breathing effort, respiratory rate >25/min
• Heart rate <40 or >130 bpm, SBP <90 mmHg1)3)
ESC guidelines recommend that patients with AHF without the criteria for intensive care 
be hospitalized in ward with only a small part of the patients discharged home from the ED 
with arranged follow-up in an outpatient clinic.1) Transferring the patient out of ICU/CCU is 
determined by stabilization of the condition.1)
First week management
Monitoring in the hospital
AHF patients should be carefully monitored in the hospital. Daily weight, supine and 
standing vital signs (pulse, respiratory rate, BP) measurements and accurate daily fluid 
balance monitoring should be maintained throughout the hospital stay. Daily assessment of 
BUN/urea, creatinine and electrolytes is preferred to monitor renal function, especially in 
patients on diuretics or when HF medications are titrated.1)2) Worsening renal function has 
been associated with worse prognosis in AHF patients.65) Multidisciplinary care is essential 
to AHF/ADHF patients, since they generally have multiple comorbidities and up to two-
thirds of their readmissions are due to causes other than HF.66) The team should consist of 
different specialists to assess comorbidities and possible causes of non-HF readmissions to 
reduce post-discharge event rate.67) Routine measurements of NPs may help with discharge 
planning.1) If not performed in the urgent phase, echocardiography should be performed 
during hospitalization or if condition deteriorates.
Evidence based oral heart failure therapies
The patient's compliance with HF medications should be reviewed at admission and 
adjustments should be made, if needed.2) In most of the patients hospitalized due to AHF, 
evidence-based heart failure oral therapy (HFOT) should be continued or even uptitrated.1-3) 
In particular, discontinuing beta-blockers has been shown to significantly increase the risk of 
AEs.68) Beta-blockers should be withheld when patient is hospitalized after recent initiation 
or increase of the dosage and in cases of CS.2) Dosage of ACE inhibitors, ARBs, MRAs should 
be reduced or temporarily discontinued in patients with hyperkalemia and significant 
worsening of renal function.1-3) Oral HF therapy should be discontinued in all patients with 
severe hypotension until condition is resolved. In new-onset AHF, clinicians should initiate 
evidence based oral therapies promptly after stabilization.3)
Discharge phase and early follow-up
In the discharge phase, clinicians should assess functional capacity of patient and potential 
exacerbating factors, optimize pharmacologic therapy and establish post-discharge plans 
together with the patient.69) Transition to oral diuretic therapy should be initiated and 
evaluated to verify its effectiveness.2) ACCF/AHA guidelines suggests that hospitalization 
presents an opportunity to properly educate the patient and family and develop adequate 
strategy for chronic treatment.2) Patient should be hemodynamically stable, decongested and 
on evidence-based HF therapy at least 24 hours before discharge.1) Guidelines underline that 
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follow-up plans must be implemented before discharge and communicated to primary care 
team.1)2) It is recommended that the patients be:
• Provided with self-care education
• Enrolled in a disease management program
• Seen by their general practitioners within 1 week of discharge and by the hospital based 
cardiologist within 2 weeks
• Followed-up within a multidisciplinary HF service1)3)
Noncompliance is one of the most important factors precipitating exacerbation of HF. 
Recognizing and assessing compliance problems and other potential precipitating factors is a 
critical step towards optimal management of AHF. Every patient should have an appropriately 
detailed evidence-based plan, preferably in writing. Staff should communicate the plan clearly 
ensuring patient's comprehension and evaluating potential issues of following the plan. In a 
randomized, controlled trial of acute HF with reduced ejection fraction patients the addition of 
a 1-hour individual teaching session with a nurse educator to the standard discharge process, 
decreased the risk of readmission or death, increased compliance, and reduced costs of care.70) 
This or similar approaches have to be studied in larger trials, but the findings are indeed 
suggesting that patient education should be an important part of the discharge phase.
OTHER CLINICAL SCENARIOS
Cardiogenic shock
CS is defined as hypotension (SBP <90 mmHg) >30 minutes despite adequate volume status 
(fluid challenge) with signs of organ hypoperfusion. It is a rare but severe phenotype of AHF.7) 
STEMI with or without mechanical complications is the most common etiology of the CS 
(80% of the cases). Non-ACS causes include worsening of congestive HF, valvular disease 
and other mechanical causes, myocarditis and stress-induced cardiomyopathy.71) ACS is 
associated with increased in-hospital mortality comparing to non-ACS causes.71) Due to high 
early mortality, CS requires urgent diagnosis of the cause, recognition of organ dysfunction 
and immediate actions. ECG and troponin are used to diagnose coronary cause of CS; 
coronary angiogram should also be considered. Early revascularization strategy is strongly 
recommended in these patients.15)54) There has been an uncertainty whether complete 
revascularization should be performed in addition to the culprit coronary lesion in cases 
of multi-vessel disease. This issue was addressed in the recent international Culprit Lesion 
Only percutaneous coronary intervention (PCI) versus Multivessel PCI in Cardiogenic Shock 
(CULPRIT-SHOCK) trial, in which the 30-day risk of a composite of death or severe renal 
failure was lower in CS patients who underwent PCI on culprit lesion only than among those 
who underwent immediate multi-vessel PCI.72)
Continuous monitoring of organ perfusion and hemodynamic status is crucial to guide the 
treatment for CS. Echocardiography should be performed immediately at admission to rule 
out mechanical complications and assess cardiac function.1)3)4) Repetitive echocardiography 
should be used for monitoring hemodynamic changes.1) Invasive monitoring with an arterial 
line is strongly recommended.73) Central venous catheter should be inserted for intermittent 
or continuous measurement of central venous oxygen saturation (ScvO2).73) A pulmonary 
artery catheter may be considered, in patients with refractory CS and RV dysfunction.73)
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After fluid challenge of up to 250 milliliters, the treatment consists of inotropes, in cases 
of low cardiac output, and vasopressor, when mean arterial pressure need pharmacologic 
support.1)73) Dobutamine should be a first-line inotropic agent.73) As an alternative, 
levosimendan may be used, especially in patients on beta-blockers at admission.73) 
Norepinephrine is the recommended vasopressor.73) The use of these agents should 
be restricted to the shortest possible duration and lowest possible dose.74) By contrast, 
increasing evidence shows that dopamine and epinephrine should not be used routinely in CS 
patients.73)75)76)
When there is an inadequate response to pharmacologic treatment, device therapy has to be 
considered.1) Intra-aortic balloon pump (IABP) is the most widely used left ventricular assist 
device (LVAD) for hemodynamic support. However, results of the recent IABP-SHOCK II 
trial did not show any mortality benefit of IABP over medical treatment in patients suffering 
from acute myocardial infarction and CS.77)78) There are several percutaneous LVADs (Impella 
[2.5, 3.5, or 5.0], Tandem Heart, and iVAC 2L) and peripheral extracorporeal membrane 
oxygenation (ECMO), which seems to be preferred by some recommendations.73) ESC 
guidelines recommend short-term mechanical circulatory support in refractory cases with IIb 
class of recommendation and C level of evidence.1) The goal for device therapy is to stabilize 
patients not responding to standard therapy, preserve organ perfusion and bridge to recovery 
or to surgical LVAD and/or to heart transplantation. Therefore, patient selection based on 
their global risk, neurological and end-organ damage is very important.4) Although more 
evidence is needed to support the use of device therapy, their use is increasing.79)
PREDOMINANT RIGHT HEART FAILURE
Rather unappreciated before, right HF has gained more recognition recently as a distinct 
clinical entity.5) AHF patients may present with predominant signs of RV failure, including 
distended jugular veins and enlarged liver. Causes of RV failure include left-sided HF, acute 
PE, RV infarction, pericardial tamponade or other deterioration in patients with pre-existing 
pulmonary vascular disease. This condition must be recognized early since it may require 
specific treatment methods and conventional management strategies may sometimes result 
in adverse outcomes.5) Urgent echocardiography is a first-line test in RV failure. It assesses RV 
size, function and load, associated valvular diseases and pulmonary pressures. Quantitative 
assessment of global RV function should be achieved by at least one of the following 
parameters: tricuspid annular plane systolic excursion (TAPSE), RV fractional are change 
(FAC), Doppler tissue imaging-derived systolic S′ velocity of the tricuspid annulus or RV index 
of myocardial performance (RIMP). Changes in biomarkers include alteration in cholestasis 
(alkaline phosphatase)27) markers, creatinine, increase in serum lactate, NPs and cardiac 
troponins.5) Precipitating factor must be corrected by urgent measures, if possible, such as 
urgent revascularization in cases of RV infarction or thrombolytic therapy in PE.5)
When treating RV failure, careful attention to RV preload is essential and excess volume 
should be avoided. Indeed, when RV afterload is increased (e.g., in pulmonary artery 
hypertension), volume loading may further overdistend the ventricles, worsen ventricular 
interdependence, and reduce cardiac output, as well as decrease coronary perfusion by 
increasing RV wall stress.5) Diuretics are often the first option to reduce RV overload for most 
patients with RV failure who present with signs of venous congestion and maintained BP. On 
the other hand, nitrates and diuretics may compromise RV preload and be deleterious. In 
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order to prevent hemodynamic compromise, volume optimization must be done cautiously.5) 
In hypotensive patients, norepinephrine is highly recommended to restore organ perfusion.5)
Hypercapnia, acidosis and alveolar hypoxia cause pulmonary artery vasoconstriction and 
further increase RV afterload.5) Correction of these conditions may be achieved by low 
level of pressure support oxygenation.4)5) Inhalation of nitric oxide22) or prostanoids80) are 
also effective options. Milrinone and levosimendan both reduce pulmonary resistance and 
increase RV contractility, which may be particularly beneficial in cases of hemodynamic 
compromise.5)81)
GAPS IN KNOWLEDGE AND PERSPECTIVES
There are several areas in AHF, which require further investigation. More extensive studies 
are needed in biomarker-guided risk stratification and treatment. “Time-to-treatment” 
concept should be investigated prospectively. There is a need in determining causes of 
readmissions and establishing appropriate strategies to prevent early readmissions after 
discharge. Many uncertainties remain in the field of acute RV failure and more evidence is 
needed regarding RV-specific treatment approaches.
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